[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371508-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371508-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","il-6-is-a-prognostic-biomarker-in-patients-with-advanced-esophageal-squamous-cell-carcinoma-received-with-pd-1-inhibitors-original-research","IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors - Original Research","","Original research investigates whether interleukin-6 (IL-6) can serve as a prognostic and predictive biomarker for patients with advanced esophageal squamous cell carcinoma (ESCC) treated with PD-1 inhibitors. The study links IL-6 with the tumor immune microenvironment using online databases and tissue microarrays, assessing PD-L1, immune and immunosuppressive cell patterns by immunohistochemistry. Baseline plasma IL-6 is evaluated in clinical follow-up to compare remission rates, PFS, and OS, including COX regression for independent risk prediction.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/il-6-is-a-prognostic-biomarker-in-patients-with-advanced-esophageal-squamous-cell-carcinoma-received-with-pd-1-inhibitors-original-research/371508/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/il-6-is-a-prognostic-biomarker-in-patients-with-advanced-esophageal-squamous-cell-carcinoma-received-with-pd-1-inhibitors-original-research/371508.png","ImageObject",300,407,{"name":42,"@type":43},"Aria Callaghan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study question does IL-6 address in advanced ESCC treated with PD-1 inhibitors?","Question",{"text":63,"@type":64},"The research explores the relationship between IL-6 and the ESCC tumor immune microenvironment and evaluates whether IL-6 predicts immunotherapy outcomes using clinical survival data.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were IL-6 and immune-related markers assessed in the study?",{"text":68,"@type":64},"TCGA RNA-seq data and TIMER 2.0 were used to examine associations between IL-6 and immune cells, while tissue microarrays measured CD8, IL-6, and PD-L1 by immunohistochemistry for microenvironment classification.",{"name":70,"@type":61,"acceptedAnswer":71},"What did high baseline IL-6 levels indicate for patient outcomes?",{"text":72,"@type":64},"Higher IL-6 expression and higher baseline plasma IL-6 were associated with lower objective remission rates and worse PFS and OS; elevated IL-6 was an independent risk factor in COX regression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371508,1790387915,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Original Research PUBLISHED 13 May 2025  \nDOI 10.3389/fimmu.2025.1569042  \nOPEN ACCESS  \nEDITED BY  \nQing Xi,  \nFirst Afﬁliated Hospital of Guangzhou Medical University, China  \nREVIEWED BY  \nGopi Sundaram,  \nCentral Food Technological Research Institute (CSIR), India  \nQitai Zhao,  \nFirst Afﬁliated Hospital of Zhengzhou University, China  \n*CORRESPONDENCE  \nHongmei Yong  \n [ha2280@126.com](ha2280@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 31 January 2025  \nACCEPTED 23 April 2025  \nPUBLISHED 13 May 2025  \nCITATION  \nHuang P, Zhao M, Xia J, Li H, Sun J, Li X, Yang C, Gao G, Zhou W, Zhong M and Yong H (2025) IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors.  \nFront. Immunol. 16:1569042 .  \ndoi: 10.3389/fimmu.2025.1569042  \nCOPYRIGHT  \n© 2025 Huang, Zhao, Xia, Li, Sun, Li, Yang, Gao, Zhou, Zhong and Yong. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors  \nPing Huang 1†, Manyi Zhao 1†, Jianhong Xia 2, Hongliang Li 2, Junxia Sun 2, Xin Li 2, Chunsheng Yang 3, Guangyi Gao 1, Wenhang Zhou 1, Meifeng Zhong 4 and Hongmei Yong 1*  \n1 Department of Medical Oncology, Huai’an Hospital Afﬁliated to Xuzhou Medical University, Huai’an, Jiangsu, China, 2 Department of Radiation Oncology, Huai’an Hospital Afﬁliated to Xuzhou Medical University, Huai’an, Jiangsu, China, 3 Department of Dermatology, Huai’an Hospital Afﬁliated to Xuzhou Medical University, Huai’an, Jiangsu, China, 4 Department of Pediatrics, Huai’an Hospital Afﬁliated to Xuzhou Medical University, Huai’an, Jiangsu, China  \nBackground: Due to the low efﬁcacy rates, effective biomarkers are desperately needed to determine populations of advanced esophageal squamous cell carcinoma (ESCC) that may beneﬁt from immune checkpoint inhibitor (ICI) treatment.  \nObjectives: To explore the relationship between IL-6 and the esophageal cancer tumor immune microenvironment using online databases and esophageal cancer tissue microarrays and to investigate the predictive role of IL-6 for immunotherapy in esophageal squamous carcinoma patients through clinical study data.  \nMethods: RNA-seq datasets of ESCC patients were obtained from TCGA, and the relationship between IL-6 and immune cells was discovered using TIMER 2.0 databases. CD8, IL-6, and PD-L1 expression in ESCC tissue microarrays were measured using immunohistochemistry, and then the tumor microenvironment was classiﬁed. Furthermore, blood specimens were collected from advanced ESCC patients before they received PD-1 inhibitors, and follow-up was conducted to gather clinical survival data. Based on IL-6 levels. We divided the population into the high and low IL-6 groups, comparing the efﬁcacy and survival of the two groups.  \nResults: IL-6 positively correlated with mRNA levels of PD-L1, negatively correlated with immune cells, and positively correlated with immunosuppressive cells. High IL-6 expression in tissues might make PD-1/L1 blockade therapy less effective. Individuals with higher baseline plasma IL-6 levels had signiﬁcantly lower objective remission rates and inferior PFS and OS. Elevated baseline IL-6 was demonstrated to be an independent risk factor for the prognosis of advanced ESCC patients using PD-1 inhibitors, according to COX regression analysis.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: IL-6 overexpression correlates with the immunosuppressive tumor microenvironme","cbCaiolawfAuHh3f","https://ap.wps.com/l/cbCaiolawfAuHh3f","pdf",3049090,13,"English","# Background\n# Objectives\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What study question does IL-6 address in advanced ESCC treated with PD-1 inhibitors?\",\"answer\":\"The research explores the relationship between IL-6 and the ESCC tumor immune microenvironment and evaluates whether IL-6 predicts immunotherapy outcomes using clinical survival data.\"},{\"question\":\"How were IL-6 and immune-related markers assessed in the study?\",\"answer\":\"TCGA RNA-seq data and TIMER 2.0 were used to examine associations between IL-6 and immune cells, while tissue microarrays measured CD8, IL-6, and PD-L1 by immunohistochemistry for microenvironment classification.\"},{\"question\":\"What did high baseline IL-6 levels indicate for patient outcomes?\",\"answer\":\"Higher IL-6 expression and higher baseline plasma IL-6 were associated with lower objective remission rates and worse PFS and OS; elevated IL-6 was an independent risk factor in COX regression.\"}]","IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors - Original Research | PDF",1790192232,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce1ddbd707c47656ba2e3afe886f9318.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/381417537b33379859179475d5ab9232.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d210dc3c692c9fa753d571f1bb476e0a.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/989ae11a1b88b87dbc7e3ff2955adf17.webp",980,1385]